In summary, our results warrant the exploration of CDK8/19i for the treatment of TNBC, both as single agents, with activity against the metastatic disease, and as combinations with approved drugs, in particular mTOR and AKT inhibitors. This evidence concerns the gene MTOR and metastatic neoplasm.